Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
-0.030 (-5.00%)
Mar 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.57 - 0.57
52 week 0.09 - 0.75
Open 0.57
Vol / Avg. 3,600.00/27,127.00
Mkt cap 35.13M
P/E 26.36
Div/yield     -
EPS 0.02
Shares 61.63M
Beta 0.84
Inst. own     -
Jan 12, 2015
Ceapro Inc at OneMedForum SF

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 28.22% 2.69%
Operating margin 29.90% 6.85%
EBITD margin - 12.90%
Return on average assets 38.64% 3.91%
Return on average equity 173.88% 136.26%
Employees 12 -
CDP Score - -


7824 51 Ave NW
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links


Ceapro Inc. (Ceapro) is a Canada-based growth stage biotechnology company. The Company�s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, renewable resources and developing innovation. The Company�s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, which are marketed to the personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales. The Company�s Veterinary therapeutic products include an oat shampoo, an ear cleanser, and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia, through agreements with Daisen Sangyo Co. Ltd.

Officers and directors

Gilles R. Gagnon President, Chief Executive Officer, Director
Age: 60
Branko Jankovic Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
William W. Li M.D. Director
Age: 49
Donald J. Oborowsky Independent Director
John Zupancic Independent Director